THE DAWN OF HUMAN REJUVENATION: FROM SCIENCE FICTION TO CLINICAL REALITY : A COMPREHENSIVE REVIEW OF CELLULAR REPROGRAMMING, SENOLYTICS, AND EPIGENETIC INTERVENTIONS

Dr. Saloni Jain; Muzzamil Tariq Chowdhary; Ritshi Amchi; Numanbhai Mansuri

Authors

Dr. Saloni Jain Assistant Teacher, Samarkand State Medical University, Uzbekistan
Muzzamil Tariq Chowdhary Medical Student, Samarkand State Medical University, Uzbekistan
Ritshi Amchi Medical Student, Samarkand State Medical University, Uzbekistan
Numanbhai Mansuri Medical Student, Samarkand State Medical University, Uzbekistan

Keywords:

Rejuvenation, cellular reprogramming, Yamanaka factors, senolytics, DNA methylation clocks

Abstract

Human aging, once considered an immutable biological certainty, is now being actively targeted by scientific interventions that demonstrate measurable age reversal at the cellular and organismal levels. This comprehensive review examines three primary therapeutic modalities leading the rejuvenation revolution: partial cellular reprogramming using Yamanaka factors, senolytic therapies targeting senescent cells, and epigenetic reprogramming through methylation-supportive interventions. Drawing from recent clinical trials, preclinical studies, and market analysis, we present evidence that biological age reversal of 4-11 years has been achieved in human subjects through non-pharmacological interventions, while cellular reprogramming has extended median remaining lifespan by 109% in aged murine models. The longevity biotechnology sector has attracted over $7.5 billion in investment between 2022-2025, signaling unprecedented institutional confidence in aging as a tractable therapeutic target. This article synthesizes current evidence for rejuvenation biology, addresses safety considerations and translational challenges, and projects the trajectory toward human clinical applications.

References

1.Fitzgerald, K. N., et al. (2022). "Potential reversal of biological age in women following an 8-week methylation-supportive diet and lifestyle program: a case series." Aging, 14(23), 9419-9432. PMC10085584.

2.National Institutes of Health. (2026). "Manipulating gene activity to reverse aging." NIH Research Matters, January 9.

3.Browder, K. C., et al. (2022). "Partial cellular reprogramming: A deep dive into an emerging rejuvenation technology." Cellular Reprogramming, PMC10861195.

4.Mayo Clinic. (2018). "Senolytics improve health, extend life: Preclinical research findings." Mayo Clinic News Network, July 9.

5.NB Science. (2026). "Advances in Anti-Aging and Longevity Stem Cell Therapy in 2025."

6.Rejuvenate Bio. (2026). "Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes." Cellular Reprogramming, February 28.

7.Hubmed Education. (2025). "Epigenetic Reprogramming: Reverse Aging at the Cellular Level."

8.National Institutes of Health. (2024). "Can we slow aging?" NIH Research Matters, October 15.

9.MarketIntelo. (2026). "Longevity Biotech Therapeutic Market Research Report 2034."

10.New Market Pitch. (2026). "Longevity Market Funding Trends (2022-2026)."